Fluorodopa F 18 in Congenital Hyperinsulinism and Insulinoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

October 9, 2013

Primary Completion Date

January 31, 2028

Study Completion Date

June 30, 2028

Conditions
Congenital HyperinsulinismInsulinoma
Interventions
DRUG

Fluorodopa F 18

A dose of Fluorodopa F 18, 3-6 MBq/Kg (0.08-0.16 mCi/kg), will be injected intravenously into the subject under the direct supervision of the radiology sub-investigator. Then, the PET imaging procedure will begin and proceed for up to 70 minutes after injection. An abdominal CT image will be made using intravenous contrast. Both images, PET and CT, will be co-localized by the radiologist for interpretation.

Trial Locations (1)

76104

RECRUITING

Cook Children's Medical Center, Fort Worth

All Listed Sponsors
lead

Cook Children's Health Care System

OTHER